Overview

Study of HS-10517 in Chinese Adult Participants

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.